Lanreotide Viatris

Lanreotide, the active ingredient in Lanreotide Viatris, is a somatostatin analog presented as a sterile solution for subcutaneous use. It is employed in the management of acromegaly and neuroendocrine tumors, helping to control excess hormone secretion in adult patients. It is indicated for adult patients who have not responded adequately to surgery or other medical therapies.

GNH USA supplies Lanreotide Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for clinical use.

Lanreotide is a somatostatin analog used to manage conditions driven by excess hormone secretion. - Acromegaly: reduces elevated growth‑hormone levels and associated clinical symptoms. - Neuroendocrine tumors (carcinoid syndrome): controls flushing and diarrhoea by inhibiting serotonin release. - GH‑secreting pituitary adenoma: helps shrink tumor size when surgery is not curative.

Lanreotide may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Injection site pain or erythema. - Abdominal discomfort or cramping. - Diarrhoea. - Nausea.

Serious or Rare Side Effects: - Gallbladder disease, including cholelithiasis. - Hyperglycaemia or new‑onset diabetes mellitus. - Acute pancreatitis. - Severe hypersensitivity reactions such as anaphylaxis.

When prescribing Lanreotide, clinicians should consider several safety aspects. - Monitor glucose: hyperglycaemia may develop, especially in patients with diabetes. - Assess gallbladder: increased risk of gallstones; watch for right‑upper‑quadrant pain. - Evaluate liver function: use caution in moderate to severe hepatic impairment. - Pregnancy and lactation: safety not established; prescribe only if benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Octreotide: additive somatostatin effects may increase gastrointestinal adverse events. - Cyclosporine: may raise lanreotide plasma concentrations. - Diazoxide: can diminish lanreotide efficacy.

Moderate Interactions (Monitor Closely): - Insulin and oral hypoglycaemic agents: glucose‑lowering effect may be altered; adjust doses as needed. - Glucagon analogues: potential antagonism of lanreotide’s inhibitory actions. - Antibiotics affecting gut flora (e.g., rifampicin): may influence peptide absorption and drug levels.